Document:

Exhibit
10.1

 

EXECUTION
COPY

 

Portions
of this document have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K

because
it is both not material and would likely cause competitive harm to the registrant if publicly

disclosed.
Redacted portions are indicated with the notation “[***].”

 

CO-PROMOTION
AGREEMENT

 

This
CO-PROMOTION AGREEMENT (this “Agreement”) is entered into as of January 15, 2021 (the “Effective
Date”) between OncoSec Medical Incorporated, a Nevada corporation with offices at 24 N Main Street, Pennington, NJ 08534
(“OncoSec”) and Sirtex Medical, Inc., a Delaware corporation with offices at 300 Unicorn Park Drive, Woburn,
MA 01801 (“Sirtex”). OncoSec and Sirtex are referred to herein collectively as the “Parties”
and each is referred to individually as a “Party.”

 

WHEREAS,
Sirtex wishes to have, and OncoSec wishes to grant to Sirtex, the option to co-promote OncoSec’s TAVO products in the Field
in the Territory, subject to the terms and conditions of this Agreement.

 

NOW
THEREFORE, in consideration of the foregoing, of the mutual covenants and undertakings contained herein, and for other good and
valuable consideration, the adequacy and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound,
hereby agree as follows:

 

1.
DEFINITIONS

 

In
addition to the capitalized terms defined elsewhere in this Agreement, the following terms shall have the following meanings when
used in this Agreement:

 

1.1
“Adverse Event” means, unless and until otherwise amended or supplemented to align with the FDA requirements,
any untoward medical outcome caused by, or associated with the use of, the Product. An Adverse Event can therefore be any unfavorable
and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the
use of the Product, including any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of
a preexisting condition that is associated with the use of the Product.

 

1.2
“Affiliate(s)” means, with respect to a Party, any company, partnership, joint venture or other entity, which
directly or indirectly controls, is controlled by or is under common control with a respective named Party. Control shall mean
the possession of more than fifty percent (50%) of the voting stock or the power to control the management and policies of the
controlled entity, whether through the ownership of voting securities, by contract, or otherwise.

 

1.3
“Applicable Laws” means all international, federal, state, or local laws, ordinances, rules, regulations, orders
or guidance, whether existing at present or later issued or enacted, that is binding on or applicable to either Party. The term
“Applicable Laws” includes, but is not limited to, the FFDCA, FDA regulations and other laws and regulations
applicable to the promotion, sales, marketing and/or distribution of the Product, the Federal Health Care Programs Anti-Kickback
Act, 42 U.S.C. § 1320a-7b(b) and its implementing regulation; the Health Insurance Portability and Accountability Act of
1996, as amended by the HITECH Act and its implementing regulations; and any laws and regulations applicable to the collection
and reporting of any payments or transfers of value to certain healthcare providers and teaching hospitals, which includes, without
limitation, the Affordable Care Act of 2010 and its implementing regulations.

 

    	 

    	 

    

 

1.4
“Authorized Representative” means a Party’s officers, directors, employees, agents, consultants, counsel,
and advisors that the Party authorizes to act in its place and on its behalf under this Agreement.

 

1.5
“Biological License Application” or “BLA” means a Biological License Application as described
in Section 351(a) of the Public Health Service Act (PHS Act), or an abbreviated Biological License Application as described in
Section 351(k) of the PHS Act (an “aBLA”), in each case in the Territory.

 

1.6
“Budget” has the meaning set forth in Section 4.6.

 

1.7
“Business Day” means a day, other than Saturday, Sunday or other day on which commercial banks in New York,
New York are authorized or required by Applicable Law to close.

 

1.8
“Combination Product” means a product that includes the Product sold in combination with one (1) or more other
pharmaceutical or biological products (each, a “Component”), each of which incorporates one (1) or more active components
other than tavokinogene telseplasmid, or one (1) or more medical devices other than the applicator and electroporation generator,
which OncoSec has the right to offer for sale, sell and have sold independent of the Product, and is either (a) packaged together
with the Product for sale or shipment as a single unit at a single price or (b) marketed and sold collectively with the Product
as a single product at a single price (including co-formulated versions of the Product).

 

1.9
“Confidential Information” means information or materials disclosed by or on behalf of the Disclosing Party
that relates to the Disclosing Party’s business or operations or to the subject matter of this Agreement and that the Receiving
Party knew or, under the circumstances should have known, was considered confidential or proprietary by the Disclosing Party.
Confidential Information includes the terms of any negotiations between the Parties, both written and oral, with respect to this
Agreement, the terms and conditions of this Agreement as well as information relating to inventory levels, product specifications,
prototypes, marketing techniques and materials, marketing plans, timetables, strategic and development plan, organizational technical
and financial data, personnel statistics, customers, patient information, trade secrets, organizational structure, business plans,
and financial information whether discussed orally or in writing.

 

    	2

    	 

    

  

1.10
“Contribution Amount” has the meaning set forth in Section 4.5.

 

1.11
“Disclosing Party” means the Party disclosing Confidential Information.

 

1.12
“Dispute” means any dispute, controversy, or claim between the Parties arising out of or under this Agreement
or its performance or termination hereof.

 

1.13
“FDA” means the U.S. Food and Drug Administration.

 

1.14
“FF Costs” has the meaning set forth in Section 4.4.

 

1.15
“FFDCA” means the US Federal Food, Drug, and Cosmetic Act, as amended.

 

1.16
“Field” means the treatment of anti-PD-1 refractory locally advanced or metastatic melanoma as defined by the
indication approved by the FDA based on the Keynote-695 clinical trial, which is expected to be for anti-PD-1 refractory locally
advanced or metastatic melanoma patients in the Territory.

 

1.17
“Field Force” has the meaning set forth in Section 4.2.

 

1.18
“FTE” means the full-time equivalent sales presentative or sales manager employee of work, which shall be pro-rated
as appropriate for any Field Force members that conduct promotional activities for products other than the Product based on the
Sales Calls conducted for the Product compared to sales calls for the other products, as reviewed by the Joint Committee.

 

1.19
“Governmental Authority” means any court, agency, authority, department, regulatory body or other instrumentality
of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision
of any such government or any supranational organization of which any such country is a member.

 

1.20
“HCP” has the meaning given in Section 8.1 hereof.

 

1.21
“Joint Committee” has the meaning set forth in Section 3.1.

 

1.22
“Net Sales” The total amount billed or invoiced on sales of the Product by OncoSec or its Affiliates to any
third party in the Field in the Territory, less the following deductions: (a) trade, cash and quantity discounts; (b) price reductions
or rebates, retroactive or otherwise, imposed by, negotiated with or otherwise paid to Governmental Authorities; (c) taxes on
sales (such as sales, value added, or use taxes) to the extent added to the sale price and set forth separately as such in the
total amount invoiced; (d) amounts repaid or credited by reason of rejections, defects, return goods allowance, recalls or returns,
or because of retroactive price reductions, including rebates or wholesaler charge backs; (e) the portion of administrative fees
paid during the relevant time period to group purchasing organizations or pharmaceutical benefit managers relating to the applicable
Product; (f) any invoiced amounts which are not collected by OncoSec or its Affiliates, including bad debts; (g) freight, insurance,
and other transportation charges to the extent added to the sale price and set forth separately as such in the total amount invoiced,
as well as any fees for services provided by wholesalers and warehousing chains related to the distribution of the applicable
Product; and (h) any other similar and customary deductions that are consistent with generally accepted accounting principles
applicable for the applicable jurisdiction. In each case the following provisions apply: Net Sales shall not include transfers
or dispositions for charitable, promotional, pre-clinical, clinical, regulatory, or governmental purposes.

 

    	3

    	 

    

 

If
a Product is sold as a Combination Product, then the total amount invoiced for such Product shall be calculated by multiplying
the total amount invoiced for such Combination Product by the fraction A/(A+B), where “A” is the total amount invoiced
for such Product sold separately and “B” is the total amount invoiced for the Component(s) sold separately. In the
event that such Component(s) are not sold separately (but such Product is), the total amount invoiced for such Product shall be
calculated by multiplying the total amount invoiced for such Combination Product by the fraction A/C, where “A” is
the total invoice amount for such Product, and “C” is the total invoice amount for the Combination Product. In the
case of a Combination Product where such Product is not sold separately, the Parties shall mutually determine in good faith an
allocation of Net Sales of such Combination Product attributable to the respective Product portion and Component(s) portion of
such Combination Product, based on the fair market value of such Product portion and such Component(s) portion.

 

For
clarity, Net Sales shall not include sales between or among OncoSec or its Affiliates. Subject to the above, Net Sales shall be
calculated in accordance with the standard internal policies and procedures of OncoSec or its Affiliates, which must be in accordance
with applicable generally accepted accounting principles in the applicable jurisdiction.

 

1.23
“Option” has the meaning set forth in Section 2.1

 

1.24
“Option Period” has the meaning set forth in Section 2.2.

 

1.25
“PDMA” means the US Prescription Drug Marketing Act of 1987, as amended, and regulations and guidelines promulgated
thereunder.

 

1.26
“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership,
corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture
or other similar entity or organization, including a government or political subdivision, department or agency of a government.

 

    	4

    	 

    

 

1.27
“Product” means the OncoSec pipeline product candidate referenced as TAVOTM (tavokinogene telseplasmid),
along with the applicator and electroporation generator.

 

1.28
“Product Trademarks” means the TAVOTM trademark and any other trademarks owned by OncoSec and used with
the Product.

 

1.29
“Promotion Fee” has the meaning set forth in Section 5.3.

 

1.30
“Promotional Materials” has the meaning set forth in Section 6.1.

 

1.31
“Promotion Plan” has the meaning set forth in Section 4.6.

 

1.32
“Receiving Party” means the Party receiving Confidential Information from the Disclosing Party.

 

1.33
“Reconciliation Report” has the meaning set forth in Section 4.5.

 

1.34
“Sales Call” means a face-to-face, video conference, or telephone call by a member of the Field Force for the
purposes of discussing and informing an HCP of the characteristics of the Product. Attendance at conventions and participation
in speaker programs and other continuing education programs shall not constitute a Sales Call.

 

1.35
“Samples” has the meaning set forth in Section 8.1 hereof.

 

1.36
“Serious Adverse Event” means an Adverse Event that results in death, is immediately life-threatening, results
in persistent and significant disability/incapacity or requires in-patient hospitalization or prolongation of existing hospitalization,
or is an overdose.

 

1.37
“Target Sales” means the target Net Sales for the Product in the Field in the Territory per calendar year,
which the initial targets included in Exhibit A.

 

1.38
“Term” has the meaning set forth in Section 12.1.

 

1.39
“Territory” means the United States of America, including its territories and possessions.

 

1.40
“Trademarks” has the meaning set forth in Section 6.3.

 

1.41
“Training Materials” has the meaning set forth in Section 7.1.

 

1.42
“Upfront Payment” has the meaning set forth in Section 5.1.

 

    	5

    	 

    

 

2.
OPTION TO CO-PROMOTE

 

2.1
Option. OncoSec hereby grants to Sirtex an option to obtain from OncoSec the non-exclusive right to co-promote the Product
in the Field in the Territory in accordance with the terms and conditions set forth in this Agreement (the “Option”).

 

2.2
Option Period. The period during which Sirtex may exercise the Option, at its sole discretion, shall commence on the Effective
Date and end upon the date that is ninety (90) days following the receipt by Sirtex of a complete copy of the final BLA filed
with the FDA by OncoSec for the approval of the Product in the Field in the Territory (the “Option Period”).

 

2.3
Option Exercise. Sirtex may exercise the Option, at its sole discretion, at any time during the Option Period by providing
written notice of Option exercise to OncoSec no later than the last day of the Option Period. Upon exercise of the Option, Sirtex
will pay to OncoSec the Option Exercise Fee set forth in Section 5.2.

 

3.
GOVERNANCE

 

3.1
Joint Committee. As soon as reasonably practicable after the Effective Date, but in no event later than thirty (30) days
following the Effective Date, a Joint Committee composed of three (3) members from each Party (the “Joint Committee”)
shall be established and the first meeting be held. Each Joint Committee member of a Party shall be notified to the other Party
in writing and shall be a senior executive of such Party. Each Party may exchange its members on the Joint Committee at any time
upon written notice to the other Party. The Parties may further decide to increase the number of members on the Joint Committee
at any time; provided, however, that the Joint Committee shall always be composed of an equal number of members
from each Party. The Joint Committee shall continue to exist throughout the Term.

 

3.2
Responsibilities. The Joint Committee shall have the following responsibilities and authority:

 

3.2.1
Oversee the co-promotion and other activities of the Parties under the Agreement;

 

3.2.2
Develop and approve an annual Promotion Plan including the Budget;

 

3.2.3
Coordinate the cooperation with respect to the development of the Promotion Plan and other ongoing activities;

 

3.2.4
Document the progress of the Promotion Plan activities and review, discuss and comment any results thereunder;

 

    	6

    	 

    

 

3.2.5
Oversee the implementation of, and monitor the progress of the Promotion Plan;

 

3.2.6
Approve updates and amendments to the Promotion Plan, including all relevant Budgets and timelines;

 

3.2.7
Review and update the composition of the Field Force set forth on Exhibit B.

 

3.2.8
Review of Promotional Materials;

 

3.2.9
Establish additional joint subcommittees, as appropriate;

 

3.2.10
Review and modify the Target Sales in Exhibit A on a periodic basis to ensure alignment;

 

3.2.11
Serve as the first forum for the settlement of disputes or disagreements resulting from or arising out of this Agreement; and

 

3.2.12
Perform such other functions as appropriate to further the purposes of this Agreement, as mutually agreed to in writing by the
Parties.

 

3.3
Meetings, Decisions of the Joint Committee.

 

3.3.1
Meetings, Agenda. The Joint Committee shall hold meetings quarterly by videoconference, telephone, web conference, or face
to face meetings, provided, that face to face meetings will be held no more than twice a year alternating between the OncoSec
and Sirtex locations, and in any case, face to face meetings are only to be held if safe from a health perspective to do so. A
quorum for a meeting of the Joint Committee will require the presence of at least one (1) member from each Party. Each Party will
cause a quorum of their members to the Joint Committee to attend all meetings thereof. OncoSec will appoint a chair for the Joint
Committee, who will be responsible for setting and distributing the agenda for each meeting and other customary duties, provided
that the chair will include in the agenda any matter raised by Sirtex for discussion at such meeting. The chair will distribute
the agenda to the Joint Committee members of the Parties no less than five (5) Business Days before any meeting of the Joint Committee.
Each Party shall in good faith consult with the other and take such other Party’s views into account in respect of any matter
before the Joint Committee, it being understood and agreed that the Parties shall not modify or amend the Agreement without mutual
agreement of the Parties.

 

3.3.2
Additional Attendees. Meetings of the Joint Committee may be attended by other employees or consultants of either Party
that are not members of the Parties on the Joint Committee; provided, however, that such attendees who are not member
of the Joint Committee: (i) shall not vote or otherwise participate in the decision-making process of the Joint Committee; (ii)
shall not be counted when determining whether a quorum exists at any such meeting; and (iii) shall be bound by obligations of
confidentiality and non-disclosure equivalent to those set forth in Article 15.

 

    	7

    	 

    

 

3.4
Meeting Minutes. Minutes setting forth, inter alia, (i) an overview of the discussions at the meeting, (ii) a list of any
actions, decisions or determinations approved by the Joint Committee, and (iii) a list of any issues to be resolved by the Joint
Committee at a subsequent meeting, will be kept of all Joint Committee meetings by chair and sent to all members of the Joint
Committee for review and approval within ten (10) days after each meeting. Minutes will be deemed approved unless any member of
the Joint Committee objects to the accuracy of such minutes by providing written notice to the other members of the Joint Committee
within five (5) Business Days of receipt of the minutes. In the event of any such objection that is not resolved by mutual agreement
of the Parties, such minutes will be amended to reflect such unresolved dispute.

 

3.5
Decision Making and Dispute Resolution. The Joint Committee will take action by unanimous consent of the Parties, with
each Party having a single vote, irrespective of the number of members on the Joint Committee or actually in attendance at a meeting,
or by a written resolution signed by at least one (1) of the designated Joint Committee members of each of the Parties. If after
reasonable discussion and good faith consideration of each Party’s view on a particular matter before the Joint Committee
and within the scope of its authority, the members of the Parties on the Joint Committee cannot reach consensus as to such matter,
then, the disputed matter shall be referred to the CEOs of each Party who shall, for forty-five (45) days after such referral,
attempt in good faith to resolve such disagreement. If such attempt fails, then OncoSec shall have the final decision-making authority
with respect to any matters relating to the Product (including, but not limited to, pricing, supply terms, manufacturing, clinical
trials). For matters related to the Field Force or the Promotion Plan, should the Parties’ respective CEOs fail to reach
agreement on a particular matter, the Joint Committee will continue to apply and adhere to the previously agreed to plans and
obligations, including the previously agreed to Promotion Plan, until such time as the matter can be resolved; provided,
however, that OncoSec may adjust its marketing budget and its marketing activities as it determines in its sole discretion.
For the avoidance of doubt, neither Party may amend the terms of the Agreement through this Joint Committee decision-making process
without the written consent of both Parties.

 

3.6
Limitations on Authority. Each Party shall retain the rights, powers, and discretion granted to it under this Agreement,
and no such rights, powers, or discretion shall be delegated to or vested in the Joint Committee unless such delegation or vesting
of rights, powers, or discretion is expressly provided for in this Agreement or the Parties expressly so agree in writing. The
Joint Committee shall have only such powers as are specifically delegated to it hereunder and in particular shall not have any
power to amend, modify, or waive compliance with this Agreement.

 

    	8

    	 

    

 

3.7
Cost of Governance. The Parties agree that the costs incurred by each Party in connection with its participation at any
meetings and other activities under this Article 3 shall be borne solely by such Party.

 

4.
CO-PROMOTION EFFECTIVE UPON OPTION EXERCISE

 

4.1
Grant of Co-Promotion Rights. Subject to the condition precedent of exercise of the Option by Sirtex pursuant to Section
2.3, including payment of the Option Exercise Fee, OncoSec hereby grants to Sirtex, during the Term of this Agreement, the non-exclusive
right to co-promote the Product in the Field in the Territory and to use the Promotional Materials in connection with such co-promotion,
in all cases subject to and in accordance with the terms of this Agreement.

 

4.2
Sirtex’s Field Force. Sirtex shall perform its co-promotion activities with respect to the Product in the Field in
the Territory as set forth in the Promotion Plan by using a sales field force composed of sales representatives and sales managers
employed by Sirtex within the Territory (all such Sirtex employees are referred to collectively as the “Field Force”).
Within sixty (60) days following the exercise of the Option, Sirtex shall establish and start training the Field Force using the
Training Materials provided by OncoSec. Sirtex shall be responsible for all acts and omissions of the Field Force. The planned
composition of the Field Force on a FTE basis is set forth in Exhibit B, which will be updated by the Joint Committee from
time to time during the Term.

 

4.3
Sirtex’s Responsibilities. Sirtex shall use commercially reasonable efforts to promote and maximize the sales of
the Product in the Field in the Territory. In performing the promotional activities under this Agreement, Sirtex shall use commercially
reasonable efforts to maintain, and promptly replace where necessary, the positions in the Field Force as described in Exhibit
B. In addition, Sirtex will distribute the Promotional Materials to the target audience as agreed upon by the Parties in the
Promotion Plan when available and legally permissible. To the extent set forth in the Promotion Plan and as allowed by Applicable
Laws, Sirtex may distribute Samples or demonstration versions of the Product to customers and will provide OncoSec with documentation
of the same. The Samples and demonstration versions of the Product will be provided by OncoSec to Sirtex at no cost, or distributed
by OncoSec directly to the relevant customers.

 

4.4
FF Costs and Cost Sharing. Sirtex shall record in its financial systems the actual costs incurred by Sirtex to co-promote
the Product in the Field in the Territory using the Field Force in accordance with this Agreement, including (a) the salaries,
bonuses, commissions, incentive payments, and related payroll taxes and benefits, for each member of the Field Force on an FTE
basis, (b) the travel, meals, and related expenses actually incurred by each member of the Field Force directly in connection
with their promotion activities for the Product, and (c) third party costs associated with training and maintaining the Field
Force specifically related to the promotion of the Product (collectively, the “FF Costs”). OncoSec shall be
responsible for funding [***] percent ([***]%) of the FF Costs incurred by Sirtex to promote the Product in the Field in the Territory
(“Contribution Amount”), and Sirtex shall be responsible for funding [***] percent ([***]%) of such FF Costs.

 

    	9

    	 

    

 

4.5
FF Costs Contribution Payments and Reconciliation. The Parties shall agree upon the Budget for the FF Costs and corresponding
Contribution Amount in the Promotion Plan as part of the annual update to the Promotion Plan conducted by the Parties through
the Joint Committee. No later than five (5) business days prior to the beginning of each month, OncoSec shall pay to Sirtex the
agreed upon Contribution Amount based on the planned FF Costs for the month as each is set forth in the Budget. Within thirty
(30) days after the end of each calendar quarter, Sirtex shall provide to OncoSec a report detailing the actual FF Costs incurred
and recorded by Sirtex in such calendar quarter, and comparing such actual FF Costs to the FF Costs set forth in the Budget for
such calendar quarter (the “Reconciliation Report”). If such actual FF Costs exceed the FF Costs set forth
in the Budget for such calendar quarter, then Sirtex will invoice OncoSec for the Contribution Amount due on the excess amount,
but in no event exceeding [***] percent ([***]%) of the FF Costs set forth in the Budget for such calendar quarter. If the FF
Costs set forth in the Budget for such calendar quarter exceed such actual FF Costs, Sirtex will provide OncoSec with a credit
notice for the Contribution Amount overpaid on the excess amount, which OncoSec will deduct from the future monthly budgeted Contribution
Amount payments. To the extent the actual FF Costs differ by more than [***] percent ([***]%) from the FF Costs set forth in the
Budget for a calendar quarter, the Joint Committee will promptly meet and review the discrepancies to attempt to improve the planning
and forecasting of the Promotion Plan.

 

4.6
Promotion Plan. Within ninety (90) days after exercise of the Option by Sirtex, and thereafter no later than ninety (90)
days prior to the beginning of each calendar year during the Term, Sirtex shall provide the members of the Joint Committee with
a written promotion plan that sets forth the promotional efforts that will be expended by Sirtex during the relevant calendar
year (or during the next twelve (12) months at the time of the Option exercise), including the planned composition of the Field
Force, the budgeted FF Costs and corresponding Contribution Amount by calendar quarter (the “Budget”),and the
target audience for the promotional efforts (the “Promotion Plan”), with OncoSec providing in that same timeframe
the marketing budget and planned activities to be included in the Promotion Plan. The Promotion Plan shall also include, at a
minimum, (i) a good faith estimate of the number of Promotional Materials and Samples that Sirtex will require during such twelve
calendar year; (ii) the geographic regions in which Sales Calls will be made during such period; (iii) the number of members of
the Field Force per region who will be performing such Sales Call; (iv) the current market share of the Product in each such region
to the extent either OncoSec or Sirtex has a reasonable estimate; (v) any trade shows, conventions, speaker programs and the like
that any member of the Field Force will attend during such period relating to the Product; and (vi) such other information as
the Joint Committee may reasonably determine. OncoSec shall have the right to make suggestions with respect to the Promotion Plan,
and Sirtex shall reasonably address any such suggestions in its implementation of the Promotion Plan. The Joint Committee will
consider, and if acceptable approve, the Promotion Plan within thirty (30) after receiving the Promotion Plan from Sirtex.

 

    	10

    	 

    

 

4.7
OncoSec’s Responsibilities. Other than the co-promotion activities undertaken by Sirtex as set forth in the Promotion
Plan or as otherwise described in this Agreement, OncoSec shall undertake directly or indirectly all other efforts in relation
to the Product in the Territory. In particular, OncoSec shall remain responsible for the development, manufacturing, and commercialization
(outside the Field Force) efforts for the Product, including the right to develop and deploy its own sales force either by itself,
by an Affiliate, or through a third party collaborator or subcontractor, as well as regulatory filings to obtain and maintain
the marketing approval of the Product, clinical trials, and other activities. In addition, OncoSec shall be responsible for the
actual supply and sales of the Product in the Territory using customary practices and in negotiating pricing and reimbursement
with governmental and private payers. OncoSec shall invoice and book all sales of the Product in the Territory, including all
sales promoted by the Field Force. OncoSec shall be responsible for all pricing, reimbursement and discounting decisions. OncoSec
shall bear all of its own costs incurred in performing its obligations under this Agreement, for any promotion of the Product
by its own sales force, and for the Contribution Amount for the Sirtex Field Force.

 

4.8
Exclusivity. During the Term, Sirtex and its Affiliates and Field Force shall not promote, commercialize, sell or distribute
in the Territory in the Field any product that is competitive to the Product. For clarity, other products utilizing different
modes of action for the treatment of melanoma will not be deemed competitive to the Product. During the Term, Sirtex and its Affiliates
and Field Force shall not promote the Product outside the Territory or outside the Field.

 

5.
FINANCIAL PROVISIONS

 

5.1
Upfront Payment. In consideration of the Option granted by OncoSec to Sirtex under this Agreement, Sirtex shall pay to
OncoSec a one-time, non-refundable lump sum fee of five million US Dollars (US$ 5,000,000) (“Upfront Payment”)
within ten (10) days after receipt of an invoice for the Upfront Payment from OncoSec after the Effective Date.

 

5.2
Option Exercise Fee. In consideration of the co-promotion and other rights granted by OncoSec to Sirtex upon Sirtex’s
exercise of the Option under this Agreement, Sirtex shall pay to OncoSec a non-refundable, non-creditable and non-cancellable
option exercise fee in the amount of twenty-five million US Dollars (US$ 25,000,000) (“Option Exercise Fee”)
as follows: (a) Sirtex shall pay OncoSec twenty million US Dollars (US$ 20,000,000) in cash within ten (10) Business Days after
OncoSec’s receipt of notice of exercise of the Option by Sirtex, and (b) Sirtex shall purchase five million US Dollars (US$
5,000,000) of OncoSec shares at a price equivalent to the average closing price for the thirty (30) days prior to the date of
the receipt of notice of exercise of the Option by Sirtex, such purchase to occur no later than ten (10) Business Days after OncoSec’s
receipt of such notice of exercise of the Option by Sirtex.

 

    	11

    	 

    

 

5.3
Promotion Fee on Sales of the Product. In consideration for Sirtex’s efforts to co-promote the Product after Sirtex’s
exercise of the Option and during the Term, OncoSec shall pay to Sirtex a royalty on the Net Sales of the Product in the Territory
in the Field at the incremental royalty rates set forth below (“Promotion Fee”):

 

5.3.1
[***] percent ([***]%) of that portion of annual Net Sales of Product in the Field in the Territory which are less than or equal
to the Target Sales; and

 

5.3.2
[***] percent ([***]%) of that portion of annual Net Sales of Product in the Field in the Territory which are more than the Target
Sales.

 

5.4
Applicability of Promotion Fee. For clarity, the Promotion Fee is only applicable to the Net Sales of the Product, including
the electroporation generator and applicator components, in the Field in the Territory. The Target Sales for each calendar year
of the Agreement are set forth on Exhibit A.

 

5.5
Net Sales Reports. OncoSec shall submit to Sirtex, within forty-five (45) days after the end of each calendar quarter,
an accurate, complete, itemized report setting forth for such calendar quarter the quantity of Net Sales in the Field in the Territory
and a calculation of the applicable Promotion Fee due thereon. Along with the report, OncoSec shall pay in full the Promotion
Fee for such calendar quarter.

 

5.6
Taxes. All payments required to be paid to Sirtex pursuant to this Agreement shall be made without deduction or withholding
for taxes, except for withholding taxes, value-added taxes and government surcharges attached to the value-added taxes required
to be deducted or withheld by OncoSec under Applicable Laws on amounts payable to Sirtex hereunder; provided, however, that OncoSec
shall provide Sirtex with a receipt in respect of any taxes deducted or withheld and remitted to the applicable Governmental Authority.
To the extent that amounts are so deducted or withheld by OncoSec, such deducted or withheld amounts shall be treated for all
purposes of this Agreement as having been paid to Sirtex as part of the payment in respect of which such deduction and withholding
was made by OncoSec. Sirtex alone shall be responsible for paying any and all taxes (other than withholding taxes, value-added
taxes and all government surcharges attached to the value-added taxes deducted and withheld on Sirtex’s behalf by OncoSec
in accordance with this Section) levied on account of, or measured in whole or in part by reference to, any payments Sirtex receives.
Without limiting the foregoing, the Parties agree to reasonably cooperate with one another in availing themselves of the benefit
of any tax treaty to minimize any applicable withholding tax with respect to payments hereunder to the extent permitted under
Applicable Law.

 

5.7
Books and Records. OncoSec shall keep, and shall require its Affiliates to keep, complete, accurate records (together with
supporting documentation) of Net Sales under this Agreement, reasonably appropriate to determine the amount of Promotion Fee due
to Sirtex hereunder (collectively “Payment Records”). Payment Records shall be retained for at least five (5) years
following the end of the reporting period to which they relate.

 

    	12

    	 

    

 

5.8
Audit. Sirtex shall have the right, once annually at its own cost and expense, to have an independent, certified public
accounting firm, selected by Sirtex and approved by OncoSec in its reasonable discretion, review Payment Records in the location(s)
where such records are maintained upon reasonable notice to OncoSec (which shall be no less than twenty (20) days prior notice)
and during regular business hours and under obligations of strict confidence, for the sole purpose of verifying the basis and
accuracy of payments made under this Agreement within the lesser of (a) the twenty-four (24) month period preceding the date of
the request for review or (b) the period after Sirtex’s most recent audit conducted under this Section 3.7 (or any other
applicable section of this Agreement) (an “Audit”). The report of such Audit shall be limited to a certificate stating
whether any report made or payment submitted by OncoSec during such period is accurate or inaccurate and the actual amounts of
Net Sales and Promotion Fee due, for such period. OncoSec shall receive a copy of each such report concurrently with receipt by
Sirtex. Should such inspection lead to the discovery of a discrepancy to Sirtex’s detriment, and only to the extent that
OncoSec agrees with and accepts such conclusion under the Audit, OncoSec shall pay within thirty (30) Business Days after its
receipt from the accounting firm of the certificate, the amount of the discrepancy plus interest calculated in accordance with
this Agreement. If OncoSec does not agree with the conclusion of such report, the matter shall be referred to dispute resolution
in accordance with this Agreement. Sirtex shall pay the full cost of the Audit unless the underpayment discovered by the Audit
is greater than five percent (5%) of the amount due for the applicable period covered by the Audit. Any overpayment by OncoSec
revealed by an Audit shall be fully creditable against future payments to be made to Sirtex hereunder.

 

6.
PROMOTIONAL MATERIALS

 

6.1
Provision of Promotional Materials. During the Term OncoSec shall prepare and provide Sirtex with promotional, informational,
training and other material approved by OncoSec with respect to the Product which will be disclosed or provided to third parties
by Sirtex in connection with its co-promotion activities under the Agreement, including without limitation any labels affixed
to Samples, Product brochures, and other promotional items referring to the Product (collectively the “Promotional Materials”).
The Joint Committee will establish a process to provide for the review of the Promotional Materials in a timely manner. If Sirtex
objects to the content of any specific information included in the Promotional Materials, the Joint Committee will review and
discuss the objections in good faith. OncoSec shall use commercially reasonable efforts to provide Sirtex with such quantities
of the Promotional Materials as Sirtex may reasonably request. OncoSec shall own all right, title and interest in and to the Promotional
Materials, and Sirtex’s right to use the Promotional Materials shall be limited to the express rights granted in this Agreement.

 

    	13

    	 

    

 

6.2
Use of Promotional Materials. Sirtex shall use the Promotional Materials solely in connection with its co-promotion of
the Product in the Field in the Territory pursuant to this Agreement, and shall not use or distribute any advertising, marketing
or other promotional materials with respect to the Product without obtaining the prior written consent of OncoSec in each instance.
Sirtex may not supplement, augment, alter or modify the Promotional Materials in any respect, and may not copy or otherwise reproduce
the Promotional Materials for any purpose without the prior written consent of OncoSec.

 

6.3
OncoSec’s Intellectual Property and Trademarks.

 

6.3.1
OncoSec shall retain ownership of all right, title and interest in and to the intellectual property, technology and other know-how
related to the Product.

 

6.3.2
OncoSec shall be responsible and control all legal actions relating to the intellectual property rights related to the Product,
including any infringement or misappropriation claims by third parties of the Product, or any enforcement or defense of the Trademarks.

 

6.3.3
Sirtex recognizes that OncoSec’s name and logo, the TAVOTM mark and logo, and similar trade dress and indicia of origin
associated with the Product, and all future trademarks associated with the Product (collectively the “Trademarks”)
represent valuable assets of OncoSec and that substantial recognition and goodwill are associated with the Trademarks.

 

6.3.4
Subject to the condition precedent of exercise of the Option by Sirtex pursuant to Section 2.3, including payment of the Option
Exercise Fee, OncoSec hereby grants to Sirtex, during the Term of this Agreement, the non-exclusive right, without the right to
sublicense, to use the Trademarks as they appear in the Promotional Materials solely in connection with the co-promotion of the
Product in the Field in the Territory. All such use of the Trademarks shall be in accordance with the directions provided by OncoSec.

 

6.3.5
Sirtex shall include the appropriate trademark registration or protection symbol (e.g., ®) with the Trademarks and all goodwill
associated with the use of the Trademarks shall inure to the benefit of OncoSec.

 

6.3.6
Except to the extent and in the form included in the Promotional Materials, Sirtex shall not, and shall instruct its Field Force
not to, use any of the Trademarks for any purpose other than as specifically permitted under this Agreement, without the prior
written consent of OncoSec in each instance; provided however that the foregoing is not intended to restrict Sirtex’
right to use the name of the Product as necessary to identify the Product in orders, invoices, and other similar non-promotional
documentation exchanged between the Parties.

 

    	14

    	 

    

 

6.3.7
Except for the limited rights granted to Sirtex to use the Trademarks as they appear in the Promotional Materials, nothing in
this Agreement is intended or shall be construed as a grant by OncoSec to Sirtex of any right, title or interest in or to any
of the Trademarks. Sirtex shall not, and shall instruct its Field Force not to, take any action inconsistent with OncoSec’s
ownership of and goodwill in the Trademarks.

 

6.3.8
Sirtex acknowledges and agrees that a breach of this Section 6.3 would cause irreparable harm to OncoSec for which money damages
and other remedies at law would not be adequate. In the event of a breach or threatened breach of this provision, OncoSec shall
be entitled to injunctive relief without the requirement of posting bond, in addition to all other remedies available to OncoSec
at law or in equity.

 

7.
TRAINING

 

7.1
Training Materials. OncoSec shall provide all training materials to be used in connection with any training on the Product
and use of the Promotional Materials (“Training Materials”), regardless of whether such training is conducted by OncoSec
or by Sirtex. The Training Materials shall provide the Field Force with information on the product and the results of the clinical
trials, including relevant safety and efficacy information. Prior to implementation, the Training Materials will be reviewed by
the Joint Committee. When Sirtex provides its Field Force with training on the Product or the Promotional Materials, it shall
use only the Training Materials provided by the OncoSec. Sirtex shall not use any training materials not provided by OncoSec without
the prior written consent of OncoSec. Each Party’s activities (other than the FF Costs) pursuant to this Article 7 shall
be at its own expense.

 

7.2
Training. OncoSec shall permit Sirtex to provide training on the Product to Sirtex’s Field Force at least once during
each twelve (12)-month period during the Term of this Agreement. Such training may be live or remote (e.g., via webinar or videoconference),
as agreed upon by the Parties, and may include representatives of OncoSec or other third parties in addition to the Field Force.
In addition to such training, Sirtex shall provide training on the Product and use of the Promotional Materials to each member
of its Field Force before such member commences to promote the Product, and shall also train each such member on promotional and
sales techniques, reporting requirements under this Agreement, Adverse Event reporting, Product sampling practices, and compliance
with Applicable Laws, including without limitation the FFDCA; the Federal Health Care Programs Anti-Kickback Act, 42 U.S.C. §
1320a-7b(b) and its implementing regulations; the statutes, regulations and written directives of Medicare, Medicaid and all other
health care programs, as defined in 42 U.S.C. §1320a-7b(f); the Health Insurance Portability and Accountability Act of 1996,
as amended by the HITECH Act and its implementing regulations; any Applicable Laws and regulations applicable to the collection
and reporting of any payments or transfers of value to certain healthcare providers and teaching hospitals, which includes, without
limitation, the Affordable Care Act of 2010 and its implementing regulations; the Pharmaceutical Research and Manufacturers of
America (“PhRMA”) Code on Interactions with Healthcare Professionals (the “PhRMA Code”); the Advanced
Medical Technology Association Code of Ethics on Interactions with Healthcare Professionals (the “AdvaMed Code”);
and the American Medical Association (“AMA”) Guidelines on Gifts to Physicians from Industry (the “AMA Guidelines”),
each as it may be amended or replaced from time to time. Each member of the Field Force must take a specific knowledge test with
respect to the Product as established by the Joint Committee, and Sirtex shall verify that such member passed such test before
such member commences to promote the Product. Sirtex shall incorporate into its training of its members of the Field Force any
suggestions or materials requested by OncoSec.

 

    	15

    	 

    

 

8.
SAMPLING

 

8.1
Demonstration Kits. OncoSec will provide Sirtex with Product demonstration kits for use by its Field Force in making Sales
Calls to healthcare providers (“HCPs”) to promote the Product (such demonstration kits are referred to herein
as the “Samples”). OncoSec shall provide the quantity of Samples as may be requested by Sirtex from time to
time during the Term, provided such quantity of samples is reasonable based upon the number of members of the Field Force distributing
them.

 

8.2
Use of Samples. Sirtex shall cause its members of the Field Force to use the Samples in strict accordance with the written
instructions therefor and any other instructions as OncoSec may provide to Sirtex from time to time, and shall store the Samples
in accordance with the labeling and any applicable storage instructions. Sirtex shall not, and shall instruct its Field Force
not to, repackage, alter the labeling of, or modify any other aspect of the Samples from the form in which they are provided by
OncoSec.

 

8.3
Sampling Compliance. During the Term of this Agreement, Sirtex shall comply with the PDMA, where applicable, and all other
Applicable Laws relating to its Field Force’s sampling of the Product. OncoSec will cooperate to assist Sirtex, as reasonably
requested, with Sample accountability, Sample returns and related matters.

 

8.4
Sampling Policies and Procedures. At least thirty (30) days prior to Sirtex’s first distribution of a Sample to an
HCP, Sirtex shall provide OncoSec a copy of Sirtex’s written policies and procedures on distribution of sample or demonstration
devices. Within thirty (30) days after receipt of such policies and procedures, OncoSec will notify Sirtex in writing whether
OncoSec believes that such policies and procedures adequately comply with Applicable Laws governing Federal and state health care
programs, including but not limited to PDMA, Federal Health Care Programs Anti-Kickback Act and similar state laws and rules and
regulations. If OncoSec determines, in its reasonable judgment, that such policies and procedures are deficient, Sirtex shall
remedy such deficiency within twenty-one (21) days with the Joint Committee cooperating to ensure the policies comply with Applicable
Laws for demonstration kits. In the event OncoSec and Sirtex do not agree upon whether the policies comply with Applicable Laws,
Sirtex will obtain an opinion from an independent external legal counsel. If Sirtex does not remedy any issues identified by OncoSec
and the external legal counsel as being contrary to Applicable Law, OncoSec may provide notice that of the Material Breach under
Section 12.2 and terminate this Agreement in accordance with that section. Any determination by OncoSec not to terminate this
Agreement pursuant to this Section 8.4 shall not imply that Sirtex’s policies and procedures are acceptable under Applicable
Laws, and shall not be deemed to relieve Sirtex of any of its obligations to comply with Applicable Laws as required under this
Agreement.

 

    	16

    	 

    

 

8.5
Reports. Where applicable, Sirtex will be responsible for making in a timely manner all reports to the FDA required under
the PDMA or otherwise required under Applicable Laws relating to its Field Force’s sampling activities under this Agreement.
Sirtex will provide to OncoSec a copy of any such report at the time of submission to the FDA. For FDA reporting purposes during
the Term of this Agreement, the definition of “significant loss” shall be the definition used by OncoSec for its own
FDA reporting purposes for the Product.

 

8.6
Audits. Sirtex shall allow OncoSec or its designee reasonable access to and the right to audit documentation associated
with distribution of Samples by or on behalf of Sirtex, including Sample requests and receipts and Field Force inventory and reconciliation
reports for three (3) years after the date of such activity. Such an audit may be conducted once in each calendar year, or more
frequently if non-compliance with sampling requirements is known or reasonably suspected by OncoSec. Sirtex will provide all requested
documents to OncoSec for such an audit or, upon OncoSec’s request, permit the audit to be conducted at its document storage
site. If during an audit of Sirtex’ sampling compliance, OncoSec determines that a PDMA or other violation of Applicable
Law has occurred but has not been reported, OncoSec may, at its discretion, report the incident to the FDA and provide written
notice to Sirtex prior to or concurrent with making such report, except to the extent prohibited by Applicable Laws.

 

9.
REPORTING 

 

9.1
Sales Call Report. Not later than forty-five (45) days after the end of each calendar quarter during the Term of this Agreement,
Sirtex shall provide OncoSec with a written report detailing: (i) by month, a breakdown of the actual number of Sales Calls performed
by or on behalf of Sirtex during such quarter; (ii) the types and names of HCPs to whom Sales Calls were made, including the medical
identification (ME) number for each HCP; (iii) for each Sales Call, whether Promotional Materials and Samples were distributed
to the HCP and, if so, the quantity thereof.

 

9.2
Report Requests. From time to time during the Term of this Agreement, OncoSec may submit reasonable written requests to
Sirtex for additional or different reports than those specified herein. Upon Sirtex’ receipt of such a request, Sirtex shall
promptly evaluate the request to determine whether it can provide the report. If Sirtex can provide the report, it shall use commercially
reasonable efforts to make the report available as soon as reasonably practicable, but in no event later than thirty (30) days
after OncoSec’s request therefor. If Sirtex cannot provide the report, it will promptly inform OncoSec of such fact and
the Parties shall consult to develop a reasonable alternative to the report requested by OncoSec.

 

    	17

    	 

    

 

9.3
Sunshine Reporting. To the extent Sirtex and its Field Force provide any payments or transfers of value to HCPs or teaching
hospitals that would be required to be reported under the Sunshine provisions of the Affordable Care Act of 2010 and its implementing
regulations, Sirtex will provide the details of such payments to OncoSec for its reporting purposes (and report itself to the
extent required by Applicable Laws).

 

10.
REGULATORY AND OTHER MATTERS

 

10.1
Adverse Event Reporting. Within ninety (90) days after exercise of the Option by Sirtex, the Parties shall discuss in good
faith and enter into a pharmacovigilance and Adverse Event reporting agreement(s) setting forth the pharmacovigilance procedures
for the Parties with respect to the Product, such as safety data sharing and Adverse Event reporting, and detailing the Parties’
respective rights and obligations with respect to any protected health information of any patients under the Health Insurance
Portability and Accountability Act of 1996 (the “Pharmacovigilance Agreement”). Prior to the execution of the
Pharmacovigilance Agreement, the Parties shall coordinate with respect to the pharmacovigilance procedures in connection with
the Product, and Sirtex shall notify the OncoSec within twenty-four (24) hours of any Adverse Event that is attributed to or potentially
attributable to the use of the Product. OncoSec will assess the aggregate safety data for the Product and inform Sirtex of any
significant changes to the safety profile of the Product, including notifying the appropriate authorities. The Parties shall establish
a reconciliation mechanism to confirm that all reports are successfully transmitted and received by the Parties. Each Party shall
also provide the other Party, on an annual basis and more frequently as reasonably requested by the other Party, a summary report
of Adverse Events, as well as those Serious Adverse Events that may not be directly attributable to the use of the Product. After
the execution of the Pharmacovigilance Agreement, the Parties shall comply with such Pharmacovigilance Agreement with respect
to all aspects of pharmacovigilance activities with respect to the Product shall be of no further effect.

 

10.2
Product Information Requests. Information received by Sirtex concerning any complaints, inquiries and/or drug information
requests from consumers, HCPs, or other third parties regarding the Product shall be forwarded to OncoSec within two (2) business
days of Sirtex’s receipt of such information and/or inquiry. OncoSec shall be responsible for responding to all complaints
and inquiries, if necessary, in accordance with its usual and customary procedures. OncoSec shall supply Sirtex, for its information
purposes only, with copies of OncoSec’s active standard response information for the Product, and with any updates thereto,
also for Sirtex’s information purposes only.

 

10.3
Governmental Reports. OncoSec shall be responsible for reporting to the FDA of Adverse Event reports relating to the Product
that it receives from third parties, from Sirtex, through safety surveillance or otherwise. Each Party shall be responsible for
making all reports to the FDA required under the PDMA with respect to that Party’s employees or other representatives (including
the Field Force in the case of Sirtex), including but not limited to notification of any theft or significant loss of Samples.
A copy of any report to FDA required under the PDMA or any other Applicable Law and any other written communication exchanged
between either Party and the FDA that relates to the Product shall be provided to the other Party upon submission, except where
precluded by any deadline imposed by any Governmental Authority, and in such case, as soon as reasonably practicable. Each Party
shall cooperate with the other and provide reasonable assistance and information as requested by the other to facilitate the requesting
Party’s filing of proper and timely PDMA and other reports required under Applicable Law.

 

    	18

    	 

    

 

10.4
Product Recall. In the event that Sirtex has reason to believe that an event, incident or circumstance has occurred which
may result in the need for a recall or other removal of any Product, or any lot or lots thereof, from the market, Sirtex shall
immediately notify the OncoSec, and the Parties shall consult with respect thereto. OncoSec shall have the sole right to determine
whether a recall or other remedial action is necessary and to take such steps as may be necessary to effect such recall or as
may be required or requested by any Governmental Authority. Sirtex shall reasonably assist in any such recall. Except as otherwise
provided herein, OncoSec shall bear all costs and expenses of a recall or other removal of Product or any lot or lots thereof
from the market. Sirtex shall reimburse OncoSec for the applicable portion of any such recall or removal costs, expenses or obligations
to the extent that the recall or removal results from Sirtex’s or any member of the Field Force’s: (i) improper distribution,
storage, or shipment of Samples; (ii) improper Product sampling practices or mishandling of Product samples; (iii) co-promotion
of the Product in a manner inconsistent with the Product’s labeling or Promotional Materials provided by OncoSec; or (iv)
violation of this Agreement.

 

10.5
Governmental Contact Reporting. Each Party shall notify the other in writing no later than three (3) business days (earlier
if necessary to permit the other Party to consult in accordance with the terms of this Agreement) of being contacted by the FDA
or any other Governmental Authority for any purpose pertaining to this Agreement or to the marketing or promotion of the Product,
including without limitation any audit regarding safety or surveillance. Sirtex shall not respond to the FDA or such other Governmental
Authority before consulting with OncoSec, unless, under the circumstances pursuant to which FDA or such other Governmental Authority
contacts Sirtex, it is not lawful or practicable to give OncoSec advance notice, in which event Sirtex shall inform OncoSec of
such contact as soon as lawful or practicable. Except where precluded by any deadline imposed by FDA or any other Governmental
Authority, and in such case, as soon as reasonably practicable, OncoSec will consult with Sirtex with respect to matters that
relate to the Product and are reasonably likely to have a material impact on Sirtex’s activities and obligations under this
Agreement prior to any meeting or other contact with FDA or any other Governmental Authority, and shall forward to Sirtex a copy
of any letter notification or report relating to such matter that is sent by OncoSec to FDA or any other Governmental Authority
upon submission or earlier if permissible as provided herein. All reporting to and consultation with each Party relating to regulatory
matters shall be made to such individual as designated by such Party to the other in writing. To the extent lawful, OncoSec shall
have the right to participate in any communication or meeting required of Sirtex by FDA or any other Governmental Authority relating
to any Product co-promoted pursuant to this Agreement.

 

    	19

    	 

    

 

11.
RECORDS; AUDIT

 

11.1
Recordkeeping by Sirtex. In addition to the other recordkeeping and audit provisions set forth in this Agreement, Sirtex
shall keep and maintain complete, detailed and accurate records and accountings related to the reports and other information required
under this Agreement.

 

11.2
Audits. OncoSec shall have the right, once annually at its own cost and expense, to have an independent, certified public
accounting firm, selected by OncoSec and approved by Sirtex in its reasonable discretion, review the records and accountings related
to the FF Costs in the locations where such records are maintained upon reasonable notice to Sirtex (which shall be no less than
twenty (20) days prior notice) and during regular business hours and under obligations of strict confidence, for the sole purpose
of verifying the basis and accuracy of payments made under this Agreement within the lesser of (a) the twenty-four (24) month
period preceding the date of the request for review or (b) the period after OncoSec’s most recent audit conducted under
this Section (or any other applicable section of this Agreement) (an “Audit”). The report of such Audit shall be limited
to a certificate stating whether any report made by Sirtex during such period is accurate or inaccurate and the actual amounts
of the FF Costs and Contribution Amounts for such period. Sirtex shall receive a copy of each such report concurrently with receipt
by OncoSec. Should such inspection lead to the discovery of a discrepancy to OncoSec’s detriment, and only to the extent
that Sirtex agrees with and accepts such conclusion under the audit, Sirtex shall pay within thirty (30) Business Days after its
receipt from the accounting firm of the certificate, the amount of the discrepancy plus interest calculated in accordance with
this Agreement. If Sirtex does not agree with the conclusion of such report, the matter shall be referred to dispute resolution
in accordance with this Agreement. OncoSec shall pay the full cost of the audit unless the overcharge discovered by the audit
is greater than five percent (5%) of the amount charged for the applicable period covered by the audit. Any undercharge by Sirtex
revealed by an audit shall be charged with the corresponding Contribution Amount to be made by OncoSec.

 

12.
TERM AND TERMINATION

 

12.1
Term. The term of this Agreement will commence upon the Effective Date and, unless earlier terminated in accordance with
this Article 12, continue until the earlier to occur of (a) the expiration of the Option Period without Sirtex exercising the
Option; or (b) the eighth (8th) anniversary of the first FDA approval of a BLA for the Product for marketing and use
in the Field in the Territory, plus any extensions of this Agreement mutually agreed upon by the Parties (the “Term”).

 

    	20

    	 

    

  

12.2
Termination for Cause. If either Party (the “Non-Breaching Party”) believes that the other Party (the
“Breaching Party”) has materially breached one or more of its material obligations under this Agreement (a
“Material Breach”), then the Non-Breaching Party may give the Breaching Party notice of such Material Breach
(a “Material Breach Notice”) specifying the nature of the breach. If the Breaching Party does not dispute that
it has committed a Material Breach, then, if the Breaching Party fails to cure such breach, or fails to take steps as would be
considered reasonable to effectively cure such breach, within sixty (60) days after receipt of the Material Breach Notice, the
Non-Breaching Party may terminate this Agreement upon written notice to the Breaching Party. If the Breaching Party disputes that
it has committed a Material Breach, the dispute shall be resolved pursuant to Section 16.7. If, as a result of the application
of such dispute resolution procedures, the Breaching Party is determined to have committed a Material Breach (an “Adverse
Ruling”), then, if the Breaching Party fails to complete the actions specified by the Adverse Ruling to cure such breach
within sixty (60) days after such ruling or such longer period as specified in the Adverse Ruling, the Non-Breaching Party may
terminate this Agreement upon written notice to the Breaching Party. The right of either Party to terminate this Agreement as
set forth in this Section 16.7 shall not be affected in any way by its waiver of, or failure to take action with respect to, any
previous default.

 

12.3
Termination for Insolvency. This Agreement may be terminated by a Party upon written notice to the other Party (a) if the
other Party shall make an assignment for the benefit of its creditors, file a petition in bankruptcy, petition or apply to any
tribunal for the appointment of a custodian, receiver or trustee for it or a substantial part of its assets, or shall commence
any proceeding under any bankruptcy, reorganization, readjustment of debt, dissolution or liquidation law or statute of any jurisdiction,
whether now or hereafter in effect; (b) if there shall have been filed against the other Party any such bona fide petition or
application, or any such proceeding shall have been commenced against it, in which an order for relief is entered or that remains
undismissed or unstayed for a period of ninety (90) days or more; (c) if the other Party by any act or omission shall indicate
its consent to, approval of or acquiescence in any such petition, application or proceeding or order for relief or the appointment
of a custodian, receiver or trustee for it or any substantial part of its assets, or shall suffer any such custodianship, receivership
or trusteeship to continue undischarged or unstayed for a period of ninety (90) days or more; or (d) anything analogous to any
of the foregoing occurs in any applicable jurisdiction. Termination pursuant to this Section 5.4 shall be effective upon the date
specified in such notice.

 

12.4
Force Majeure. In the event that an event of force majeure (i) lasts for more than six (6) months and (ii) has a material
adverse effect on the performance of the obligations of the affected Party, the non-affected Party shall have the right to terminate
this Agreement, immediately by written notice to the affected Party.

 

12.5
OncoSec Buy-Back. OncoSec shall have the right to terminate the Agreement at any time during the Term upon giving Sirtex
three (3) months prior written notice, and paying Sirtex a termination fee equal to the product of [*** million US Dollars (US$
[***]) multiplied by the sum of the number of whole calendar years and fractions of calendar years remaining in the Term on the
effective date of termination, but in no event exceeding [***] million U.S. Dollars (US$ [***) (the “Termination Fee”).
The Termination Fee shall be paid no later than the effective date of termination under this Section 12.5.

 

    	21

    	 

    

 

12.6
Payment Upon Expiration. Upon any expiration, but not termination, of this Agreement, and further provided that
the Target Sales have been met for the sum of the four (4) calendar quarters immediately preceding such expiration, OncoSec shall
pay to Sirtex a one-time payment to cover the wind-down costs for the Field Force actually incurred by Sirtex (e.g., severance
payments, termination payments, etc.), but in no event exceeding the aggregate amount of Promotion Fees paid by OncoSec to Sirtex
for the three (3) months immediately preceding such expiration. Sirtex shall provide OncoSec an invoice and detailed accounting
of such wind-down costs no later than ninety (90) days after the expiration date of the Agreement to obtain such payment from
OncoSec under this Section 12.6.

 

12.7
Effects of Expiration and Termination. Upon any expiration or termination of this Agreement for any reason, the rights
granted to Sirtex shall terminate, and Sirtex shall deliver to OncoSec any and all of its inventory of Samples and Promotional
Materials, and shall discontinue use of and return any Confidential Information relating to the Product. Expiration or termination
of this Agreement for any reason shall not relieve the Parties of their respective rights or obligations incurred prior to the
effective date of expiration or termination. The rights and remedies of the Parties are cumulative and not exclusive of any rights
or remedies available at law, in equity, under this Agreement or otherwise.

 

13.
INDEMNIFICATION

 

13.1
Definitions.

 

13.1.1
“Claim” means any third party claim, demand, action, suit, or proceeding whether civil, criminal, administrative,
or investigative, in which either Party may be involved, or threatened to be involved as a party, that may give rise to the other
Party’s indemnification obligation.

 

13.1.2
“OncoSec Indemnified Parties” means OncoSec, its Affiliates, and its and their respective agents, employees,
officers, and directors.

 

13.1.3
“Indemnifiable Losses” means the aggregate of Losses and Litigation Expenses.

 

13.1.4
“Indemnified Parties” means, in the case of OncoSec, the OncoSec Indemnified Parties, and in the case of Sirtex,
the Sirtex Indemnified Parties.

 

    	22

    	 

    

 

13.1.5
“Litigation Expenses” means any court filing fees, court costs, mediation fees or costs, witness fees, and
the cost of investigating and defending or asserting any claim, including reasonable attorneys’ fees, other professionals’
fees, and disbursements.

 

13.1.6
“Losses” means any liabilities, losses, claims, settlement payments, costs and expenses, interests, awards,
judgments, damages, fines, fees and penalties, or other charge, other than a Litigation Expense.

 

13.1.7
“Sirtex Indemnified Parties” means Sirtex, its Affiliates and its and their respective agents, employees, officers,
and directors.

 

13.2
General Indemnification Obligations. Each Party will indemnify, defend and hold the other Party harmless from and against
any Indemnifiable Losses incurred by such other Party or its Indemnified Parties in connection with a Claim arising out of or
relating to (i) the indemnifying Party’s negligent act or omission or willful misconduct in connection with this Agreement,
including the negligent act or omission or willful misconduct of the indemnifying Party or any of its agents, employees, or other
representatives (including, in the case of Sirtex, the members of the Field Force), and including any Claim for personal injury
or property damage related to or caused by the foregoing; or (ii) any material breach of this Agreement by the Indemnifying Party.

 

13.3
Sirtex’ Indemnification. In addition to and without limiting the indemnification obligations set forth in Section
13.2, Sirtex will indemnify, defend and hold the OncoSec Indemnified Parties harmless from and against any Indemnifiable Losses
incurred by any of the OncoSec Indemnified Parties in connection with a Claim arising out of or relating to (i) off-label promotions
by Sirtex or any members of its Field Force with respect to the co-promotion of the Product (except to the extent the Claim is
based on Sirtex’s use of the Promotional Materials in accordance with the terms of this Agreement); or (ii) any violation
of approved labeling or Applicable Law with respect to Sirtex’s and its Field Force’s co-promotion of the Product
(other than claims based on the use of the Promotional Materials or other items provided by OncoSec for purposes of co-promoting
the Product), including without limitation any violation of the FFDCA; the Federal Health Care Programs Anti-Kickback Act, 42
U.S.C. § 1320a-7b(b); the statutes, regulations and written directives of Medicare, Medicaid and all other health care programs,
as defined in 42 U.S.C. §1320a-7b(f).

 

13.4
OncoSec’s Indemnification. In addition to and without limiting the indemnification obligations set forth in Section
13.2, OncoSec will indemnify, defend and hold the Sirtex Indemnified Parties harmless from and against any Indemnifiable Losses
incurred by any of the Sirtex Indemnified Parties in connection with a Claim arising out of or relating to (i) Sirtex’s
use of the Promotional Materials, the Samples, or the Trademarks, in each case in the form provided by OncoSec and in each case
as used in accordance with the terms of this Agreement; (ii) the infringement (or any claim of infringement) or misappropriation
of any intellectual property or other proprietary rights (including patents, copyrights, trademarks, and trade secrets) of a third
party for the Product or by Sirtex’s use of the Promotional Materials, Samples, or Trademarks in accordance with the terms
of this Agreement; or (iii) the failure by OncoSec to provide Product that meets its relevant specifications, including any related
claims of product liability; or (iv) any violation of approved labeling or Applicable Law with respect to Sirtex’s and its
Field Force’s co-promotion of the Product through the use of Promotional Materials or other items provided by OncoSec for
purposes of co-promoting the Product in accordance with the terms of this Agreement.

 

    	23

    	 

    

 

13.5
Procedural Issues

 

13.5.1
A Party is not obligated to defend or indemnify the other Party’s Indemnified Parties for any Indemnifiable Losses to the
extent those losses arise from the Indemnified Party’s negligence or willful misconduct.

 

13.5.2
The Party seeking indemnification (the “Indemnified Party”) will give the indemnifying Party prompt notice
of any Claim. The Indemnified Party will cooperate with the indemnifying Party, at the indemnifying Party’s expense, by
complying with its reasonable instructions and requests in connection with the preparation for and defense of the Claim. The Indemnified
Party, at its option and expense, may hire counsel to assist in defending the Claim.

 

13.5.3
The indemnifying Party will not compromise or settle any Claim that adversely affects the Indemnified Party or admits any matter
concerning the Indemnified Party without the Indemnified Party’s prior written consent. The Indemnified Party’s failure
to provide the indemnifying Party with prompt written notice of a Claim will not discharge the indemnifying Party’s indemnification
obligations under this section unless and to the extent that the failure or delay in providing the notice materially prejudices
the indemnifying Party’s ability to defend the Claim.

 

13.6
Disclaimer of Consequential and Certain Other Damages. EXCEPT FOR (I) EACH PARTY’S INDEMNIFICATION OBLIGATIONS HEREUNDER,
(II) DAMAGES ARISING OUT OF EITHER PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS HEREUNDER, OR (III) DAMAGES ARISING
OUT OF EITHER PARTY’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR
ANY SPECIAL, CONSEQUENTIAL OR INCIDENTAL DAMAGES ARISING UNDER OR AS A RESULT OF THIS AGREEMENT OR THE TERMINATION HEREOF.

 

14.
REPRESENTATIONS AND WARRANTIES

 

14.1
Representations and Warranties of the Parties. Each Party hereby represents and warrants to the other Party that:

 

14.1.1
Such Party is a corporation duly organized, validly existing and in good standing under the laws of the state of its incorporation;
has the corporate power and authority to conduct the business in which it presently is engaged, to enter into this Agreement,
and to perform its obligations hereunder; and is in good standing in each jurisdiction in which the failure to be in good standing
would have a material adverse effect upon its business or financial condition.

 

    	24

    	 

    

 

14.1.2
All corporate action on the part of such Party necessary for the authorization, execution, and delivery of this Agreement and
for the performance of all of such Party’s obligations hereunder has been taken, and this Agreement, when executed and delivered,
shall constitute a valid and legally binding obligation of such Party enforceable in accordance with its terms, except as enforceability
may be limited by bankruptcy, insolvency and other laws affecting creditors’ rights generally or by general equitable principles.

 

14.1.3
The execution, delivery, and performance by such Party of this Agreement does not constitute a breach or default under any contract
or agreement to which such Party is a party or by which it is bound or otherwise violate the rights of any third party or any
Applicable Law.

 

14.2
Additional Representations and Warranties of Sirtex. Sirtex’s Field Force shall perform Sales Calls in accordance
with approved labeling for the Product and all Applicable Laws. Without limiting the foregoing, in performing the co-promotion
activities contemplated by this Agreement, Sirtex and its Field Force shall comply with all Applicable Laws governing Federal
and state health care programs, including, without limitation, the FFDCA, the PDMA, the Federal Health Care Programs Anti-Kickback
Act, 42. U.S.C. Section 1320a-7b and its implementing regulations, and similar state laws; the statutes, regulations and written
directives of Medicare, Medicaid and all other health care programs, as defined in 42 U.S.C. §1320a-7b(f); the Health Insurance
Portability and Accountability Act of 1996, as amended by the HITECH Act and its implementing regulations; any Applicable Laws
and regulations applicable to the collection and reporting of any payments or transfers of value to certain healthcare providers
and teaching hospitals, which includes, without limitation, the Affordable Care Act of 2010 and its implementing regulations;
the Pharmaceutical Research and Manufacturers of America (“PhRMA”) Code on Interactions with Healthcare Professionals
(the “PhRMA Code”); the Advanced Medical Technology Association Code of Ethics on Interactions with Healthcare Professionals
(the “AdvaMed Code”); and the American Medical Association (“AMA”) Guidelines on Gifts to Physicians from
Industry (the “AMA Guidelines”), each as it may be amended or replaced from time to time.

 

14.3
NO OTHER WARRANTIES. EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 14, (A) NO REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER
IS MADE OR GIVEN BY OR ON BEHALF OF EITHER PARTY; AND (B) ALL OTHER REPRESENTATIONS AND WARRANTIES WHETHER ARISING BY OPERATION
OF LAW OR OTHERWISE ARE EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE OR NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY.

 

    	25

    	 

    

 

15.
CONFIDENTIAL INFORMATION

 

15.1
Term of Confidentiality; Exceptions to Definitions. During the Term of this Agreement and for a period of five (5) years
thereafter, each Party shall hold Confidential Information of the other Party confidential and shall not disclose the other Party’s
Confidential Information to any third party except as expressly permitted herein. Confidential Information does not include information:

 

15.1.1
that was known to the Receiving Party before receiving it pursuant to this Agreement and that knowledge can be documented, and
was not received directly or indirectly from the Disclosing Party;

 

15.1.2
from and after the date that such information is obtained from a third party who rightly had possession of it and who disclosed
it to the Receiving Party without an obligation of secrecy;

 

15.1.3
that becomes knowledge of the general public through no act, fault or omission of the Receiving Party; or

 

15.1.4
that is released from this provision by written agreement of the Disclosing Party.

 

15.2
Use of Confidential Information. In no event shall either Party use Confidential Information of the other Party except
to perform under this Agreement. The Receiving Party may disclose the Disclosing Party’s Confidential Information to those
of its employees, representatives (including, in the case of Sirtex, members of its Field Force), agents, directors, officers,
Affiliates, and professional advisors who have a need to know such information in order for the Receiving Party to perform hereunder,
provided that each of the foregoing is subject to confidentiality obligations with respect to such Confidential Information at
least as restrictive as those set forth herein.

 

15.3
Required Disclosure. The Receiving Party may disclose Confidential Information of the Disclosing Party when required by
a court order or Applicable Law, subject to the provisions of this Section 15.3. In such event, the Receiving Party shall promptly
notify the Disclosing Party of the need for the disclosure and give the Disclosing Party a reasonable time, if possible, to oppose
or seek confidential treatment of the disclosure. The Receiving Party shall cooperate with the Disclosing Party in such efforts.
In addition, the Receiving Party will disclose only the minimum amount of Confidential Information required to comply with the
court order.

 

    	26

    	 

    

 

16.
MISCELLANEOUS 

 

16.1
Independent Contractors. OncoSec and Sirtex are independent contractors engaged in the operation of their own respective
businesses. Neither Party is the agent or employee of the other Party or of any of the other Party’s employees or contractors
for any purpose. Neither Party has authority to enter into contracts or assume any obligation for or on behalf of the other Party
or to make any warranties or representations for or on behalf of the other Party. Neither Party’s employees are eligible
to participate in any benefits programs offered by the other Party to its employees, or in any pension plans, profit sharing plans,
insurance plans or any other employee benefits plans offered by the other Party. Sirtex acknowledges and agrees that it is solely
responsible for designing and administering any incentive program to its Field Force with respect to their activity promoting
the Product; and for paying all salaries, wages, benefits and other compensation to which members of its Field Force may be entitled
to receive in connection with the performance of this Agreement.

 

16.2
Severability. The Parties intend that this Agreement will be enforceable under Applicable Laws. If a court of law
or arbitral panel holds any provision of this Agreement unenforceable, in whole or in part, all other provisions of this Agreement
will remain in effect. To the extent possible, the Parties will amend this Agreement to modify any unenforceable provision to
render it valid and enforceable.

 

16.3
Assignment. Neither Party may assign any of its rights or obligations under this Agreement without the prior written
consent of the other Party, provided that either Party may assign or delegate this Agreement without prior written consent
of the other Party to: (a) an Affiliate; or (b) a third-party in connection with a sale or transfer of all or substantially all
of such Party’s business to which this Agreement relates, whether in a merger, sale of stock, sale of assets, reorganization
or other transaction. Any attempted assignment not in accordance with this Section 16.3 shall be null and void and of no legal
effect.

 

16.4
Participation in Federally Funded Healthcare Programs. Each Party represents and warrants that it is not an Excluded
Provider and that it will not directly contract with any individual whom it knows or should have known after reasonable inquiry
is an Excluded Provider. For purposes of this paragraph, “Excluded Provider” means a person or entity that
either (a) has been convicted of a criminal offense related to health care or (b) is currently listed by a federal agency as debarred,
excluded, suspended, or ineligible to participate in federally funded health care programs or in federal procurement or nonprocurement
programs. In furtherance of this requirement, each Party agrees to make reasonable inquiry as to any existing or prospective employee,
agent, subcontractor, or independent contractor it considers for engagement to perform services under this Agreement by reviewing
the General Services Administration’s List of Parties Excluded from Federal Programs and the HHS/OIG Cumulative Sanction
Report. Each Party shall notify the other in writing within five (5) days of any change in this representation or if circumstances
change to render this representation false during the Term of this Agreement.

 

    	27

    	 

    

 

16.5
Anti Kickback Act Compliance. Each Party represents, warrants and covenants that it is not currently using, and will not
in the future use, in connection with the performance under this Agreement, the services of any Ineligible Person (as defined
below). Each Party shall immediately notify the other Party in writing if any person who is performing hereunder is or becomes
an Ineligible Person or if any action, suit, claim, investigation, or other legal or administrative proceeding is pending or,
to the best of its knowledge, threatened, that would make any person performing hereunder an Ineligible Person or would preclude
either Party from performing its obligations under this Agreement. Each Party shall require each Person providing services hereunder
to be bound by agreements that require substantially the same compliance as the foregoing warranty and covenant. Neither Party
nor any person performing hereunder appears on either the Department of Human Health & Services/Office of Inspector General
List of Excluded Individuals/Entities, found at http://www.oig.hhs.gov or the General Services Administration’s List of
Parties Excluded from Federal Programs, found at http://www.epls.gov. For purposes of this section, an “Ineligible Person”
shall be any individual or entity who: (i) is currently excluded, debarred, suspended or otherwise ineligible to participate in
federal health care programs or in federal procurement or nonprocurement programs; (ii) has been convicted of, or is under investigation
for, a criminal offense that is governed by 42 U.S.C. §1320a-7(a) related to the provision of health care items or services,
but has not yet been excluded, debarred, suspended or otherwise declared ineligible; or (iii) is debarred or subject to debarment
under 21 U.S.C. §335a or otherwise disqualified or suspended from performing services or otherwise subject to any restrictions
or sanctions by the FDA.

 

16.6
Non-discrimination. As applicable, the provisions of Executive Order 11246, as amended by E0 11375 and E0 11141 and as
supplemented in Department of Labor regulations (41 CFR Part 60 et. seq.), are incorporated into this Agreement. Each Party hereby
certifies by signing this Agreement that all services are provided without discrimination on the basis of race, color, religion,
national origin, disability, sex, or veteran’s status; each Party does not maintain nor provide for its employees any segregated
facilities, nor will either Party permit its employees to perform their services at any location where segregated facilities are
maintained. In addition, each Party agrees to comply with Section 504 of the Rehabilitation Act and the Vietnam Era Veteran’s
Assistance Act of 1974, 38 U.S.C. Section 4212. “Segregated facilities”, as used in this provision, means any
waiting rooms, work areas, restrooms, wash rooms, restaurants and other eating areas, time clocks, locker rooms and other storage
or dressing areas, parking lots, drinking fountains, recreation or entertainment areas, transportation, and housing facilities
provided for employees, that are segregated by explicit directive or are in fact segregated on the basis of race, color, religion,
or national origin because of habit, local custom, or otherwise.

 

    	28

    	 

    

 

16.7
Dispute Resolution/Governing Law Procedure. This Section 16.7 sets forth the exclusive dispute resolution procedures for
any Dispute. Nothing set forth in this Section 16.7 is intended to limit either Party’s right to seek specific performance,
injunctive relief or provisional remedies in any court of competent jurisdiction.

 

16.7.1
Negotiation. Each Party’s Authorized Representative who has the authority to waive or settle the Dispute, must meet
within ten (10) Business Days after one Party notifies the other in writing about the Dispute. All negotiations pursuant to this
clause are confidential and the Parties shall treat the negotiations as settlement negotiations.

 

16.7.2
Litigation. If the Parties cannot resolve the Dispute after negotiating in good faith for at least sixty (60) days, either
Party may initiate litigation.

 

16.7.3
Governing Law/Venue. This Agreement shall be construed and interpreted in accordance with the laws of the State of New
York, without regard to its principles concerning the application of laws of other jurisdictions, with exclusive jurisdiction
of the courts of the State of New York located in NY City, or the United States District Court for the Southern District of New
York, and to the exclusion of the UN Convention on Contracts for the International Sale of Goods (CISG).

 

16.7.4
Litigation Costs and Expenses. Each Party shall bear its own costs and expenses, including attorneys’ fee, in connection
with any Dispute.

 

16.8
Entire Agreement. This Agreement constitutes the entire agreement between the Parties concerning its subject matter and
supersedes all prior written or oral agreements or understandings between them with respect to the subject matter of this Agreement.
No modification of this Agreement will have any force or effect unless the modification is in writing, specifically references
this Agreement, and is signed by Authorized Representatives of each Party. This Agreement is valid only when signed by Authorized
Representatives of each Party.

 

16.9
Notices. Any notices or communications required or contemplated by this Agreement must be in writing and sent, properly
addressed to the addresses listed below. Notice shall be deemed effective upon delivery. Notices must be sent as follows:

 

16.9.1
next-day delivery by a nationally recognized delivery service such as Federal Express; or

 

16.9.2
certified or registered mail, postage prepaid, return receipt requested. [NOTE: Parties to confirm notice information.]

 

	 	To
    Sirtex:	300
                                         Unicorn Park Drive

        2nd
        Floor

        Woburn,
        MA 01801

        Attn:
        General Counsel

        [***]

 

    	29

    	 

    

 

	 	With
    a copy to:	300
                                         Unicorn Park Drive

        2nd
        Floor

        Woburn,
        MA 01801

        Attn:
        Legal Dep’t

        [***]

	 	 	 
	 	To
    OncoSec:	OncoSec
                                         Medical Incorporated

        24
        N Main Street

        Pennington,
        NJ 08534

        Attn:
        Daniel J. O’Connor, President and CEO

        [***]

	 	 	 
	 	With
    a copy to	McDermott
                                         Will & Emery LLP

        340
        Madison Avenue

        New
        York, NY 10173-1922

        Attn:
        Robert H. Cohen

        [***]

 

16.10
Waiver. No waiver of any breach or failure by either Party to enforce any of the terms or conditions of this Agreement
at any time will, in any manner, limit or waive the Party’s right to enforce and to compel strict compliance with that and
every other term and condition hereof.

 

16.11
Use of Trademarks and Press Releases. Except as otherwise expressly permitted by this Agreement, neither Party shall
use the name, insignia, symbol, trademark, trade name or logotype of the other Party (or any abbreviation or adaptation thereof)
in any publication, press release, promotional material, or other form of publicity without the prior written approval of the
other Party. The restrictions imposed by this Section shall not prohibit either Party from making any disclosure identifying the
other Party that is required by Applicable Law or contemplated by this Agreement. Except as otherwise required by Applicable Law,
each Party shall not and shall not permit its Affiliates to issue or cause the publication of any press release or make any other
public announcement with respect to this Agreement, without the prior written consent of the other Party. The Parties agree to
cooperate in the preparation of all public announcements related to this Agreement, if any, and shall furnish drafts of any releases
and announcements to the other Party within a reasonable time prior to their proposed release.

 

16.12
Counterparts. This Agreement may be executed in one or more counterparts, including by facsimile or electronic copy,
all of which shall be considered one and the same agreement. This Agreement shall become effective when an Authorized Representative
of each Party has signed and delivered to the other Party at least one such counterpart.

 

    	30

    	 

    

 

16.13
Prohibition on Gifts and Gratuities. OncoSec may not offer gifts or other items of value including cash, free goods,
merchandise, tickets to sporting or entertainment events, special discounts, honoraria, liquor, food products, personal services,
preferential treatment, reimbursement or payment for travel expenses, lodging, or meals to Sirtex employees, members of the Field
Force, officers, or directors or their family members. This prohibition is a condition of doing business with Sirtex and a material
term of this Agreement. If OncoSec violates this policy, it will be in material breach of the terms of this Agreement, and Sirtex
shall have the right to immediately terminate this Agreement, regardless of whether the gift or benefit is accepted.

 

16.14
Survival. In addition to any provisions that by their nature are intended to survive expiration or termination of
this Agreement, the provisions of Sections 1, 12.6, 12.7, 13, 14, 15 and 16, shall survive expiration or termination of this Agreement.

 

16.15
Other Provisions. Except where the context requires otherwise, whenever used in this Agreement the singular includes
the plural, the plural includes the singular, and the term “including” or “includes” means including,
without limiting the generality of any description preceding that term. When this Agreement refers to a number of days, unless
otherwise specified as business days, that reference is to calendar days. The headings in this Agreement are provided for convenience
only and do not affect its meaning. The wording of this Agreement shall be deemed wording mutually chosen by the Parties and no
rule of strict construction shall be applied against either Party. Any reference in this Agreement to a Section, Article, Schedule,
or Exhibit is to a Section, Article, Schedule, or Exhibit of this Agreement. Unless specified otherwise, any reference to a statute
means that statute and any successor statute and regulations promulgated under it, all as amended or supplemented from time to
time. To the extent the provisions of this Agreement and any Schedule or Exhibit conflict, the provisions of this Agreement supersede
and control.

 

16.16
Authority. The individuals executing this Agreement on behalf of each Party represent that they have authority to bind
such Party.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	31

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

 

	 	OncoSec
    Medical Incorporated
	 	 	 
	 	By:	 
	 	Title:	                   
	 	Date:	 
	 	 	 
	 	SIRTEX
    MEDICAL, INC. 
	 	 	 
	 	By:	 
	 	Title:	 
	 	Date:	 

 

    	32

    	 

    

 

EXHIBIT
A

 

Target
Sales

 

The
Parties will cooperate to modify this Exhibit to be on a calendar year basis following the exercise of the Option and the joint
agreement on a Launch Date for the Product.

 

	Starting
    from Launch	 	 	Year
                                         1	 	Year
    2	 	Year
                                         3	 	Year
                                         4	 	Year
    5	 	Year
                                         6	 	Year
    7	 	Year
    8	 
	Target
    Sales (in USD millions)	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 

 

    	33

    	 

    

 

EXHIBIT
B

 

Field
Force Composition

 

The
Joint Committee will update the target composition of the Field Force and this Exhibit throughout the Term. As of the Term Sheet,
the parties estimate that the Field Force will consist of the following FTEs by category.

 

	Starting
    from Launch	 	 	Year
    1	 	Year
    2	 	Year
    3	 	Year
    4	 	Year
    5	 	Year
    6	 	Year
    7	 	Year
    8	 
	Sales
    Reps	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 
	Managers	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 
	Total	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 

 

    	34Document

DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF     THE SECURITIES EXCHANGE ACT OF 1934

The following summary of the terms of our capital stock is not meant to be complete and is qualified by reference to the relevant provisions of the Delaware General Corporation Law and our amended and restated certificate of incorporation, as amended (our “certificate of incorporation”), and our second amended and restated by-laws (our “by-laws”). 
Authorized Capital Stock
Our certificate of incorporation authorizes us to issue up to 150,000,000 shares of common stock, $0.01 par value per share, and 50,000,000 shares of preferred stock, $0.01 par value per share. 
Description of Common Stock
Voting rights.  Each share of common stock is entitled to one vote on all matters voted upon by our stockholders, including the election of directors, and do not have cumulative voting rights.  Holders of our common stock are entitled to elect all of the members of the class of directors whose term is expiring, subject to the rights of holders of preferred stock, by a plurality vote.  Unless otherwise required by law, our certificate of incorporation or by-laws, any matter brought before any meeting of stockholders, other than the election of directors, is decided by the affirmative vote of a majority of the shares present in person or represented by proxy and entitled to vote thereon, a quorum being present.
Dividends.  Holders of our common stock are entitled to receive dividends when, as and if declared by our board of directors out of funds legally available therefor and subject to the rights of holders of preferred stock.   
Liquidation rights.  Holders of common stock are entitled to share ratably in all assets legally available for distribution to holders of our common stock in the event of our liquidation, winding up or dissolution, subject to the rights of holders of preferred stock. 
Other rights and preferences.  The issued and outstanding shares of our common stock are, and the shares of our common stock that we may issue in the future will be, validly issued, fully paid and nonassessable. Shares of our common stock are not redeemable, have no sinking fund provisions, and have no subscription, conversion or preemptive rights. Transfer agent. The transfer agent and registrar for our common stock is Computershare Inc. 
NASDAQ. Our common stock is listed on The Nasdaq Global Market under the symbol “STRS.”
Certain Provisions of Our Certificate of Incorporation and By-laws
Classified Board. Our board of directors has been divided into three classes, with each class consisting, as nearly as possible, of one-third of the total number of the directors and serving a three-year term. This classification of our board of directors may prevent our stockholders from changing the membership of the entire board of directors in a relatively short period of time. At least two annual meetings, instead of one, generally will be required to change the majority of directors. The classified board provisions could have the effect of prolonging the time required for one of our stockholders with significant voting power to gain majority representation on our board of directors. Where approval by a majority of the directors is necessary for a transaction, such as in the case of an interested stockholder business combination (as discussed below), the inability to gain majority representation on the board of directors immediately could discourage takeovers and tender offers. 
Supermajority Voting/Fair Price Requirements. Our certificate of incorporation provides that the approval of the holders of not less than 85 percent of our outstanding common stock is required for:
•Any merger or consolidation of our company or any of our subsidiaries with or into any person or entity, or any affiliate of that person or entity, who was within the two years prior to the transaction a beneficial owner of 20 percent or more of our outstanding common stock, which we refer to as an interested party;
•any merger or consolidation of an interested party with or into our company or any of our subsidiaries;
•any sale, lease, exchange, mortgage, pledge, transfer or other disposition of more than 10 percent of the fair market value of the total assets of our company or any of our subsidiaries in one or more transactions involving an interested party;
•the adoption of any plan or proposal for liquidation or dissolution of our company proposed by or on behalf of any interested party;

•the issuance or transfer by us or any of our subsidiaries of securities of our company having a fair market value of $1 million or more to any interested party in one or more transactions; or
•any recapitalization, reclassification, merger or consolidation of our company or any of our subsidiaries that would increase an interested party’s voting power in our company or any of our subsidiaries.
However, the 85 percent voting requirement is not applicable if
•our board approves the transaction, or approves the acquisition of the common stock that caused the interested person to become an interested person, and the vote includes the affirmative vote of a majority of our directors who are not affiliates of the interested party and who were members of our board prior to the time the interested party became the interested party;
•the transaction is solely between us and any of our wholly owned subsidiaries or between any of our wholly owned subsidiaries; or
•the transaction is a merger or consolidation and the consideration to be received by our common stockholders is at least as high as the highest price per share paid by the interested party for our common stock on the date the common stock was last acquired by the interested party or during a period of two years prior.
Effects of Authorized but Unissued Common Stock and Blank Check Preferred Stock. One of the effects of the existence of authorized but unissued common stock and undesignated preferred stock may be to enable our board of directors to make more difficult or to discourage an attempt to obtain control of our company by means of a merger, tender offer, proxy contest or otherwise, and thereby to protect the continuity of management. If, in the due exercise of its fiduciary obligations, the board of directors were to determine that a takeover proposal was not in our best interest, such shares could be issued by the board of directors without stockholder approval in one or more transactions that might prevent or render more difficult or costly the completion of the takeover transaction by diluting the voting or other rights of the proposed acquirer or insurgent stockholder group, by putting a substantial voting block in institutional or other hands that might undertake to support the position of the incumbent board of directors, by effecting an acquisition that might complicate or preclude the takeover, or otherwise.
In addition, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized but unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance also may adversely affect the rights and powers, including voting rights, of those holders and may have the effect of delaying, deterring or preventing a change in control of our company.
Advance Notice of Intention to Nominate a Director. Our by-laws permit a stockholder to nominate a person for election as a director only if written notice of such stockholder’s intent to make a nomination has been delivered to our Secretary within the time periods and in the manner specified in the by-laws. Any nomination that fails to comply with these requirements may be disqualified.
Advance Notice of Stockholder Proposals. Our by-laws permit a stockholder proposal to be presented at a stockholders’ meeting only if prior written notice of the proposal has been delivered to our Secretary within the time periods and in the manner specified in the by-laws.
No Ability of Stockholders to Call Special Meetings. Our certificate of incorporation and by-laws provide that, except to the extent that holders of preferred stock have the right to call a special meeting in some circumstances, only the board of directors, the chairman of the board, or the president may call special meetings of the stockholders.
No Ability of Stockholders to Act by Written Consent. Our certificate of incorporation denies our stockholders the right to take any action required or permitted to be taken at any annual or special meeting of stockholders by written consent.
Removal of Directors; Filling Vacancies on Board of Directors. Under the Delaware General Corporation Law, a director on a classified board may be removed only for cause by a vote of the shareholders. Our certificate of incorporation and by-laws provide that newly created directorships resulting from any increase in the number of directors and any vacancies on the board of directors resulting from the death, resignation, disqualification or removal of a director, or other reason, may be filled only by a majority vote of the remaining directors, regardless of any quorum requirements. Any director so elected will hold office for the remainder of the full term of the class of directors in which the new directorship was created or the vacancy occurred and until such director’s successor has been elected and qualified.

Supermajority Voting Requirement. The affirmative vote of at least 85 percent of our outstanding capital stock is required to amend, alter, change or repeal the provisions in our certificate of incorporation providing for the fair price requirements described above. In addition, our certificate of incorporation and our by-laws require the affirmative vote of at least 85 percent of our outstanding capital stock to amend, alter, change or repeal the provisions providing for the classified board structure, and the provisions prohibiting stockholders to act by written consent, to call a special meeting or to fill a vacancy on the board of directors.
Amendment of By-laws. Our certificate of incorporation and by-laws provide that the by-laws may be altered, amended, changed or repealed by vote of the stockholders or at any meeting of the board of directors by the vote of a majority of the directors present or as otherwise provided by statute.
Limitation of Liability of Directors and Officers. As permitted by the Delaware General Corporation Law, our certificate of incorporation includes a provision that eliminates the personal liability of our directors for monetary damages for breach of fiduciary duty as a director, except for liability (1) for any breach of the director’s duty of loyalty to our company or its stockholders, (2) for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, (3) under section 174 of the Delaware General Corporation Law or (4) for any transaction from which the director derived an improper personal benefit. The effect of this provision is to eliminate our rights and our stockholder’s rights to recover monetary damages against a director for breach of a fiduciary duty of care. The provision does not eliminate or limit our right, or the right of a stockholder, to seek non-monetary relief, such as an injunction or rescission. In addition, our certificate of incorporation provides for mandatory indemnification rights to the fullest extent permitted by law to any director or executive officer who (because of the fact that he or she is our director or officer) is involved in a legal proceeding. These indemnification rights include reimbursement for expenses incurred by the director or officer in advance of the final disposition of a proceeding according to applicable law.
Forum for Adjudication of Disputes
Our by-laws provide that to the fullest extent permitted by law, and unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (1) any derivative action or proceeding brought in the name or right of our company or on its behalf, (2) any action asserting a claim for breach of a fiduciary duty owed by any director, officer, employee, stockholder or other agent of the company to the company or our stockholders, (3) any action arising or asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or any provision of our certificate of incorporation or by-laws or as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware or (4) any action asserting a claim governed by the internal affairs, doctrine, including, without limitation, any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or by-laws. Any person or entity purchasing or otherwise acquiring any interest in share of our company’s stock will be deemed to have notice of and consented to these provisions.
Description of Preferred Stock
Our board of directors may, without stockholder approval, authorize us to issue shares of preferred stock in series and may, at the time of issuance, determine the rights, preferences and limitations of each series, including but not limited to dividend, voting, conversion and liquidation preference rights. Satisfaction of any dividend preferences of outstanding shares of preferred stock would reduce the amount of funds available for the payment of dividends on shares of common stock. Holders of shares of preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up of our company before any payment is made to the holders of shares of common stock. In some circumstances, the issuance of shares of preferred stock may render more difficult or tend to discourage a merger, tender offer or proxy contest, the assumption of control by a holder of a large block of our securities or the removal of incumbent management. The issuance of any shares of preferred stock in the future could adversely affect the rights of the holders of common stock.
Description of Series D Participating Cumulative Preferred Stock Purchase Rights
On September 22, 2020, our board of directors adopted a stockholder rights agreement (as amended, the “Rights Agreement”) between the company and Computershare Inc., as rights agent. On March 12, 2021, we entered into an Amendment to the Rights Agreement. Pursuant to the Rights Agreement, our board of directors declared a dividend of one right (a “Right”) for each outstanding share of our common stock, to stockholders of record at the close of business on October 2, 2020 (the “Record Date”). Each Right entitles its holder, subject to the terms of the Rights Agreement, to purchase from the company one one-hundredth of a share of Series D Participating Cumulative Preferred Stock, par value $0.01 per share (“Series D Preferred Stock”), of the company at an exercise price of $150 per Right, subject to adjustment.

Our board of directors approved the Rights Agreement in an effort to protect stockholder value by attempting to provide for the preservation of the company’s ability to potentially convert from a C-Corporation to a real estate investment trust (“REIT”) under the U.S. Internal Revenue Code of 1986, as amended. The Rights Agreement limits, subject to certain exceptions as set forth in the Rights Agreement, a person’s or group’s ability to own 9.8% or more of our common stock, as calculated in accordance with the Rights Agreement (the “Ownership Threshold”), which ownership or deemed ownership in excess of the Ownership Threshold may threaten the Company’s potential REIT status. The Rights Agreement should not interfere with any merger or other business combination approved by our board of directors.
The Rights. From the Record Date until the Distribution Date (as defined below) or the Expiration Date (as defined below) the Rights will trade with, and be inseparable from, shares of our common stock. New Rights will attach to any shares of common stock that become outstanding after the Record Date and prior to the earlier of the Distribution Date and the Expiration Date. Until the Distribution Time, the surrender for transfer of any shares of our common stock will also constitute the transfer of the Rights associated with those shares. The Rights are not exercisable until the Distribution Time. Until a Right is exercised, its holder will have no rights as a stockholder of the Company, including the right to vote or to receive dividends.
Separation and Distribution of Rights; Exercisability. Subject to certain exceptions, the Rights become exercisable and trade separately from our common stock only upon the “Distribution Time,” which occurs upon the earlier of:

•(i) the close of business on the tenth (10th) day after the “Stock Acquisition Date” (which is defined as (a) the first date of public announcement that any person or group has become an “Acquiring Person,” which is defined as a person or group that, together with its affiliates and associates, beneficially owns the Ownership Threshold or more of the outstanding shares of common stock (with certain exceptions, including those described below) or (b) such other date, as determined by our board of directors, on which a person or group has become an Acquiring Person); or
•the close of business on the tenth (10th) business day (or such later date as may be determined by our board of directors prior to such time as any person or group becomes an Acquiring Person) after the commencement of or first public announcement of intent to commence a tender offer or exchange offer that, if consummated, would result in a person or group becoming an Acquiring Person.
An Acquiring Person does not include:

•the company or any subsidiary of the company;
•any officer, director or employee of the company or any subsidiary of the company in his or her capacity as such;
•any employee benefit plan of the company or of any subsidiary of the company or any entity or trustee holding (or acting in a fiduciary capacity in respect of) shares of capital stock of the company for or pursuant to the terms of any such plan or for the purpose of funding other employee benefits for employees of the company or any subsidiary of the company;
•any person or group that, together with its affiliates and associates, beneficially owns the Ownership Threshold or more of the outstanding shares of common stock will not, as determined by our board of directors in its sole discretion, adversely impact, jeopardize or endanger the potential availability to the Company of its REIT status; or
•any person or group that, together with its affiliates and associates, as of immediately prior to the first public announcement of the adoption of the Rights Agreement, beneficially owns the Ownership Threshold or more of the outstanding shares of our common stock so long as such person or group continues to beneficially own at least the Ownership Threshold of the outstanding shares of common stock and does not acquire shares of common stock to beneficially own an amount equal to or greater than the greater of (a) the Ownership Threshold and (b) the sum of the lowest beneficial ownership of such person or group since the public announcement of the adoption of the Rights Agreement plus one share of common stock.

In addition, the Rights Agreement provides that no person or group will become an Acquiring Person as a result of share purchases or issuances directly from the company or through an underwritten offering approved by our board of directors. Also, a person or group will not be an Acquiring Person if our board of directors determines that such person or group has become an Acquiring Person inadvertently and such person or group as promptly as practicable divests a sufficient number of shares so that such person or group would no longer be an Acquiring Person.
Certain synthetic interests in securities created by derivative positions, whether or not such interests are considered to be ownership of the underlying common stock or are reportable for purposes of Regulation 13D of the Securities Exchange Act of 1934, as amended, are treated as beneficial ownership of the number of shares of common stock equivalent to the economic exposure created by the derivative position, to the extent actual shares of common stock are directly or indirectly held by counterparties to the derivatives contracts. 

Expiration Time. The Rights will expire on the earliest to occur of (a) the close of business on September 22, 2023 (the “Final Expiration Time”), (b) the time at which the Rights are redeemed or exchanged by the company (as described below), (c) upon the closing of certain merger or other acquisition transactions involving the company pursuant to a merger or other acquisition agreement that has been approved by our board of directors before any person or group becomes an Acquiring Person, (d) the time at which the company’s conversion to a REIT under the Code becomes effective, and (e) the close of business on December 31, 2021 unless stockholder approval of the Rights Agreement has been obtained on or prior to such time (the earliest of (a), (b), (c), (d) and (e) being herein referred to as the “Expiration Time”).
Flip-In Event. In the event that any person or group (other than certain exempt persons) becomes an Acquiring Person (a “Flip-In Event”), each holder of a Right (other than such Acquiring Person, any of its affiliates or associates or certain transferees of such Acquiring Person or of any such affiliate or associate, whose Rights automatically become null and void) will have the right to receive, upon exercise, common stock having a value equal to two times the exercise price of the Right.
For example, at an exercise price of $150.00 per Right, each Right not owned by an Acquiring Person (or by certain related parties) following a Flip-In Event would entitle its holder to purchase $300.00 worth of common stock for $150.00. Assuming that our common stock had a per share value of $22.00 at that time, the holder of each valid Right would be entitled to purchase 13.64 shares of our common stock for $11.00 per share.
Flip-Over Event. In the event that, at any time following the Stock Acquisition Date, directly or indirectly, any of the following occurs (each, a “Flip-Over Event”):

•the company consolidates with, or merges with and into, any other entity (other than a direct or indirect, wholly-owned subsidiary of the company), and the company is not the continuing or surviving entity;
•any entity (other than a direct or indirect, wholly-owned subsidiary of the company) engages in a share exchange with or consolidates with, or merges with or into, the company, and the company is the continuing or surviving entity and, in connection with such share exchange, consolidation or merger, all or part of the outstanding shares of common stock are converted into or exchanged for stock or other securities of any other entity or cash or any other property; or
•the company sells or otherwise transfers, in one transaction or a series of related transactions, fifty percent (50%) or more of the company’s assets, cash flow or earning power,
each holder of a Right (except Rights which previously have been voided as described above) will have the right to receive, upon exercise, common stock of the acquiring company having a value equal to two times the exercise price of the Right.
Series D Preferred Stock Provisions. Each share of Series D Preferred Stock, if issued: will not be redeemable, will entitle the holder thereof to quarterly dividend payments equal to the greater of $100 per share and 100 times the amount of all cash dividends plus 100 times the amount of non-cash dividends or other distributions paid on one share of our common stock, will entitle the holder thereof to receive $100 plus accrued and unpaid dividends per share upon liquidation, will have the same voting power as 100 shares of common stock and, if shares of common stock are exchanged via merger, consolidation or a similar transaction, will entitle the holder thereof to a per share payment equal to the payment made on 100 shares of common stock.

Anti-dilution Adjustments. The exercise price payable, and the number of shares of Series D Preferred Stock or other securities or property issuable, upon exercise of the Rights are subject to adjustment from time to time to prevent dilution:

•in the event of a stock dividend on, or a subdivision, combination or reclassification of, the Series D Preferred Stock;
•if holders of the Series D Preferred Stock are granted certain rights, options or warrants to subscribe for Series D Preferred Stock or convertible securities at less than the current market price of the Series D Preferred Stock; or
•upon the distribution to holders of the Series D Preferred Stock of evidences of indebtedness or assets (excluding regular quarterly cash dividends) or of subscription rights or warrants (other than those referred to above).
 
With certain exceptions, no adjustment in the exercise price will be required until cumulative adjustments amount to at least 1% of the exercise price. The company shall not be required to issue fractional shares of Series D Preferred Stock and, in lieu thereof, an adjustment in cash will be made based on the market price of the Series D Preferred Stock on the last trading day prior to the date of exercise.
Redemption; Exchange. At any time prior to the earlier of (i) the tenth day following the Stock Acquisition Date or (ii) Final Expiration Time, the company may redeem the Rights in whole, but not in part, at a price of $0.001 per Right (subject to adjustment and payable in cash, common stock or other consideration deemed appropriate by our board of directors). Immediately upon the action of our board of directors authorizing any redemption, the Rights will terminate and the only right of the holders of Rights will be to receive the redemption price for each Right so held.
At any time after any person or group becomes an Acquiring Person and prior to the time that any Acquiring Person, together with all of its affiliates and associates, becomes the beneficial owner of fifty percent (50%) or more of the outstanding shares of our common stock, the company may exchange the Rights (other than Rights owned by the Acquiring Person, any of its affiliates or associates or certain transferees of Acquiring Person or of any such affiliate or associate, whose Rights will have become null and void), in whole or in part, at an exchange ratio of two shares of our common stock, or two one-hundredths of a share of Series D Preferred Stock (or of a share of a class or series of the Company’s preferred stock having equivalent rights, preferences and privileges), per Right (subject to adjustment).
Amendment of the Rights Agreement. The company and the Rights Agent may from time to time amend or supplement the Rights Agreement without the consent of the holders of the Rights. However, on or after the Stock Acquisition Date, no amendment can materially adversely affect the interests of the holders of the Rights (other than the Acquiring Person any of its affiliates or associates or any transferee of any Acquiring Person or any such affiliate or associate thereof).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]